CD279 antibodies

CD279 antibodies

Clone: PD1.3.1.3
PD1.3.1.3 recognizes human CD279, also known as programmed death-1 (PD-1). It is a 55 kDa transmembran protein belonging to the CD28/CTLA-4 family. It is expressed on T cells, B cells, NK cells, and activated myeloid cells. CD279 is not expressed on naive T cells but induced after activation and expressed on late, differentiated T cells. The ligands PD-L1 (B7-H1; CD274) and PD-L2 (B7-DC; CD273) belong to the B7 immunglobulin superfamily. PD1 and its ligands mediate inhibitory signals that regulate the balance between T cell activation, tolerance, and immunopathology. Clone PD.1.3.1.3 has been used to block the binding of both ligands.

Applications

Reagent can be used for immunophenotyping by flow cytometry. Abnormal numbers of cells expressing this antigen or aberrant expression levels of the antigen can be expected in some disease states. It is important to understand the normal expression pattern for this antigen and its relationship to expression of other relevant antigens in order to perform appropriate analysis.
Expression of CD279 may be used as aid to diagnostic in the characterization of samples from individuals suspected with hematologic neoplasia.

Technical specifications

  • Antigen: CD279
  • Clone: PD1.3.1.3
  • Isotype: mouse IgG2bκ
  • Molecular mass of antigen [kDa]: 29
  • Distribution of antigen: B cells, monocytes, spleen, T cells, thymocytes
  • Product format: Reagents are supplied in buffer containing stabilizer and 0.05% sodium azide.
  • Storage: Store protected from light at 2–8 °C. Do not freeze.
  • Available conjugates: APC, PE
  • Selected references

    1. Serriari, N.-E. et al. (2010) B and T lymphocyte attenuator is highly expressed on CMV-specific T cells during infection and regulates their function. J. Immunol. 185: 3140-3148
    2. Okazaki, T. and Honjo, T. (2007) PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19: 813-824
    3. Keir, M. E. et al. (2008) PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26: 677-704
    4. Stelzer GT et al. (1997) U.S.-Canadian consensus recommendations on the immunophenotypic analysis of hematologic neoplasia by flow cytometry: standardization and validation of laboratory procedures. Cytometry 30(5): 214-230
    5. Rothe, G et al. (2012) Consensus protocol for the flow cytometric Immunophenotyping of hematopoietic malignancies. Leukemia 10(5): 877-895
    6. van Dongen, J. J. M. et al. (2012) EuroFlow antibody panels for standardized n-dimensional flow cytometric immunophenotyping of normal, reactive and malignant leukocytes. Leukemia 26(9): 1908-1975
    7. Clinical and Laboratory Standards Institute (CLSI) (2007) Clinical Flow Cytometric Analysis of Neoplastic Hematolympoid Cells, CLSI document H43-A2 (ISBN 1-56238-635-2) CLSI; Approved Guideline - Second Edition
    8. Clinical and Laboratory Standards Institute (CLSI) (2007) Enumeration of immunologically defined cell populations by flow cytometry, CLSI document H42-A2 (ISBN 1-56238-640-9) CLSI; Approved Guideline - Second Edition
    9. Kishimoto, T et al. (eds) Leucocyte typing VI: White cell differentiation antigens. Garland Publishing Inc., New York
  • gentleMACS Protocols

  • Certificates

    Please follow this
    link
    to download the Certificate of Conformity (CoC) by lot number.
Product options: 2
170-078-044

CD279-PE

for 50
tests
EUR 330,00 
170-078-092

CD279-APC

for 50
tests
EUR 330,00